Diabetes decisions — 2025

The Board denied service connection for sickle cell anemia, urinary incontinence, diabetes mellitus II, erectile dysfunction, and sleep apnea as the evidence did not support a current diagnosis or a link to service.

The Board denied the Veteran's claims for service connection for chronic kidney disease and diabetes mellitus type II, finding no evidence of an in-service injury or event related to these conditions.

The Board granted service connection for coronary artery disease, diabetes mellitus, type II, and hypertension due to in-service exposure to herbicide agents. The claims for peripheral neuropathy of the upper and lower extremities and erectile dysfunction were denied.

The appeal was dismissed due to the appellant's death during the pendency of the appeal.

The Board denied the Veteran's claim for service connection for diabetes mellitus, type II as it was not shown to be related to his in-service duties or any herbicide exposure.

The Board remands the claims for service connection for diabetes and esophageal cancer due to incomplete evidence regarding herbicide exposure.

The Board denied service connection for hypertension, atrial fibrillation, diabetes mellitus, type II, premature atrial contraction, and prostate cancer as there was no evidence of in-service injury or disease related to these conditions.

The Board granted a total disability rating based on individual unemployability (TDIU) but denied increased ratings for shin splints and PTSD, and remanded the claim for service connection for type II diabetes.

The Board granted service connection for hypertension, diabetes, and kidney disease as secondary to post-traumatic stress disorder (PTSD) but denied service connection for hyperlipidemia.

The Board denied earlier effective dates for the awards of service connection and increased ratings, as well as a compensable rating for allergic rhinitis.

The Board granted service connection for diabetes mellitus, type II, with diabetic nephropathy and diabetic retinopathy, coronary artery disease with cardiac stent status-post acute myocardial infarction, and hypertension under the PACT Act, effective February 13, 2023.

The Board granted service connection for diabetes mellitus, type II due to herbicide exposure and related conditions (lower extremity neuropathy and erectile dysfunction) but denied upper extremity neuropathy.

The Board denied service connection for diabetes mellitus, head trauma, and PTSD due to the lack of new and relevant evidence. The Veteran was granted an initial 10% disability rating for migraines but had other claims remanded or denied.

The Board granted service connection for diabetes mellitus type 2 and hypertension, finding that both conditions are etiologically related to the Veteran's military service. The claims for traumatic brain injury, syncopal episodes, headaches, and loss of sense of smell were remanded for further development.

The Board granted service connection for an acquired psychiatric disorder, diagnosed as specific phobia, situation type (enclosed places, flying), and remanded the claim for diabetes mellitus. The other claims were denied.

The Board denied the veteran's claims for increased ratings and service connection, except for obstructive sleep apnea which was granted, and granted a total disability rating for compensation purposes due to individual unemployability (TDIU).

The Board granted service connection for PTSD and dismissed the claim for diabetes. The claims for service connection for teeth and TDIU were remanded.

The Board denied the veteran's claims for increased ratings and earlier effective dates, finding that the evidence did not support higher ratings or earlier effective dates.

The appeal of entitlement to service connection for diabetes mellitus type II was dismissed, while the appeals for peroneal neuritis and increased evaluation for right foot plantar fasciitis were granted. The issues related to osteoarthritis and pes cavus were remanded.

The Board granted the restoration of a 20% rating for Type II diabetes mellitus and a 10% rating for laryngeal cancer residuals, effective November 14, 2020. The Board also granted a 30% rating for dysphagia and a separate 10% rating for neck scar residuals under 7804.